WO2002002744A3 - Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof - Google Patents
Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof Download PDFInfo
- Publication number
- WO2002002744A3 WO2002002744A3 PCT/US2001/021350 US0121350W WO0202744A3 WO 2002002744 A3 WO2002002744 A3 WO 2002002744A3 US 0121350 W US0121350 W US 0121350W WO 0202744 A3 WO0202744 A3 WO 0202744A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- human mch1
- mch1
- nucleic acid
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002507986A JP2004502423A (en) | 2000-07-05 | 2001-07-05 | DNA encoding human melanin-concentrating hormone receptor (MCH1) and use thereof |
AU73207/01A AU7320701A (en) | 2000-07-05 | 2001-07-05 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
CA002384358A CA2384358A1 (en) | 2000-07-05 | 2001-07-05 | Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
EP01952456A EP1246847A2 (en) | 2000-07-05 | 2001-07-05 | Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61063500A | 2000-07-05 | 2000-07-05 | |
US09/610,635 | 2000-07-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002002744A2 WO2002002744A2 (en) | 2002-01-10 |
WO2002002744A3 true WO2002002744A3 (en) | 2002-08-08 |
Family
ID=24445829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/021350 WO2002002744A2 (en) | 2000-07-05 | 2001-07-05 | Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1246847A2 (en) |
JP (1) | JP2004502423A (en) |
AU (1) | AU7320701A (en) |
CA (1) | CA2384358A1 (en) |
WO (1) | WO2002002744A2 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221613B1 (en) | 1998-12-31 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
CA2414198A1 (en) | 2000-07-06 | 2002-01-17 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US7078484B2 (en) | 2001-04-19 | 2006-07-18 | Neurogen Corporation | Melanin concentrating hormone receptors |
US7078187B2 (en) | 2001-04-19 | 2006-07-18 | Neurogen Corporation | Melanin concentrating hormone receptors |
AU2002305323A1 (en) | 2001-05-04 | 2002-11-18 | Tularik Inc. | Fused heterocyclic compounds |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
MXPA03010612A (en) | 2001-05-22 | 2004-04-02 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues. |
US6727264B1 (en) | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
CN1671386A (en) * | 2001-07-05 | 2005-09-21 | H·隆德贝克有限公司 | Substituted anilinic piperidines as MCH selective antagonists |
US7199135B2 (en) | 2001-07-05 | 2007-04-03 | H. Lundbeck A/S | Substituted alkyl amido piperidines |
US7105544B2 (en) * | 2001-07-05 | 2006-09-12 | Synaptic Pharmaceutical Corporation | Substituted alkyl amido piperidines |
JP2005532991A (en) | 2002-01-10 | 2005-11-04 | ニューロジェン・コーポレーション | Melanin-concentrating hormone receptor ligand: substituted 2- (4-benzyl-piperazin-1-ylmethyl)-and 2- (4-benzyl-diazepan-1-ylmethyl) -1H-benzimidazole analogs |
JP2005526709A (en) | 2002-01-10 | 2005-09-08 | ニューロジェン・コーポレーション | Melanin-concentrating hormone receptor ligand: substituted benzimidazole analogs |
UA77814C2 (en) | 2002-07-03 | 2007-01-15 | Lundbeck & Co As H | Spirocyclic piperidines as antagonists of mch1 and use thereof |
UA77536C2 (en) * | 2002-07-03 | 2006-12-15 | Lundbeck & Co As H | Secondary aminoaniline piperidines as mch1 antagonists and their use |
DE60329513D1 (en) | 2002-07-30 | 2009-11-12 | Banyu Pharma Co Ltd | ANTAGONIST OF MELANINE CONCENTRATING HORMONE RECEPTOR, CONTAINING A BENZIMIDAZOLE DERIVATIVE AS AN ACTIVE SUBSTANCE |
WO2004023870A1 (en) * | 2002-09-10 | 2004-03-25 | Takeda Pharmaceutical Company Limited | Human slt transgenic animal |
MXPA05004739A (en) | 2002-11-06 | 2005-08-02 | Tularik Inc | Fused heterocyclic compounds. |
CA2515717A1 (en) | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co., Ltd. | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
AU2004241213B2 (en) | 2003-05-21 | 2009-04-23 | Banyu Pharmaceutical Co., Ltd. | 2-aminoquinoline derivative |
US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
US7241787B2 (en) | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
CN1930126A (en) * | 2004-03-05 | 2007-03-14 | 万有制药株式会社 | Pyridone derivative |
DE102004039789A1 (en) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals |
WO2007018248A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
WO2007024004A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
JPWO2007029847A1 (en) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | Bicyclic aromatic substituted pyridone derivatives |
AU2007214711A1 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
UY31968A (en) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | NEW HETEROCYCLIC DERIVATIVES, THEIR PROCESSES FOR THEIR PREPARATION, AND THEIR THERAPEUTIC USES |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
UY32442A (en) | 2009-02-13 | 2010-09-30 | Sanofi Aventis | NEW SUBSTITUTED INDANS, PROCESSES FOR THEIR PREPARATION AND USE OF THE SAME AS A MEDICINAL PRODUCT |
TW201040153A (en) | 2009-02-13 | 2010-11-16 | Sanofi Aventis | Novel substituted tetrahydronaphthalenes, process for preparation thereof and use thereof as medicaments |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2012120057A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0848060A2 (en) * | 1996-12-11 | 1998-06-17 | Smithkline Beecham Corporation | Novel human 11CB splice variant |
WO2001005947A1 (en) * | 1999-07-14 | 2001-01-25 | Merck & Co., Inc. | Melanin-concentrating hormone receptor |
-
2001
- 2001-07-05 AU AU73207/01A patent/AU7320701A/en not_active Abandoned
- 2001-07-05 JP JP2002507986A patent/JP2004502423A/en active Pending
- 2001-07-05 EP EP01952456A patent/EP1246847A2/en not_active Withdrawn
- 2001-07-05 CA CA002384358A patent/CA2384358A1/en not_active Abandoned
- 2001-07-05 WO PCT/US2001/021350 patent/WO2002002744A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0848060A2 (en) * | 1996-12-11 | 1998-06-17 | Smithkline Beecham Corporation | Novel human 11CB splice variant |
WO2001005947A1 (en) * | 1999-07-14 | 2001-01-25 | Merck & Co., Inc. | Melanin-concentrating hormone receptor |
Non-Patent Citations (6)
Title |
---|
C.R. ACAD. SCI. III, SCI. VIE., vol. 318, no. 2, 1995, pages 263 - 272 * |
DATABASE GENBANK [online] 20 February 1995 (1995-02-20), AUFFRAY, C. ET AL.: "HSC1ZF101 normalized infant brain cDNA homo sapiens cDNA clone c-1zf10, mRNA sequence", XP002950954, Database accession no. (F07228) * |
DATABASE GENBANK [online] accession no. EMBL Database accession no. (AF008650, P97639) * |
DATABASE GENBANK [online] accession no. EMBL Database accession no. (U71092, Q99705) * |
KOLAKOWSKI, L.F. ET AL.: "Characterization of a human gene related to genes encoding somatostatin receptors", FEBS LETTERS, vol. 398, no. 2-3, 19 December 1996 (1996-12-19), pages 253 - 258, XP002916551 * |
LAKAYE, B. ET AL.: "Cloning of the rat brain cDNA encoding for the SLC-1 G protein-coupled receptor reveals the presence of an intron in the gene", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1401, no. 2, 1998, pages 216 - 220, XP000856696 * |
Also Published As
Publication number | Publication date |
---|---|
AU7320701A (en) | 2002-01-14 |
WO2002002744A2 (en) | 2002-01-10 |
CA2384358A1 (en) | 2002-01-10 |
EP1246847A2 (en) | 2002-10-09 |
JP2004502423A (en) | 2004-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002002744A3 (en) | Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof | |
WO2000039279A3 (en) | Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof | |
WO2000050562A3 (en) | Dna encoding snorf25 receptor | |
GR960300009T1 (en) | ||
Claeysen et al. | Cloning, expression and pharmacology of the mouse 5-HT4L receptor | |
CA2129969A1 (en) | DNA Encoding 5-HT4 Serotonin Receptors and Uses Thereof | |
WO2004064774A3 (en) | Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof | |
CN114058617A (en) | Conjugated antisense compounds and uses thereof | |
EP1063292A3 (en) | DNA encoding human alpha 1 adrenergic receptors and uses thereof | |
WO2015139051A2 (en) | Nanocarriers and their processing for diagnostics and therapeutics | |
Liao et al. | A nuclear DNA-binding protein expressed during early stages of B cell differentiation interacts with diverse segments within and 3'of the Ig H chain gene cluster. | |
Kuo et al. | Regulation of insulin degradation: expression of an evolutionarily conserved insulin-degrading enzyme increases degradation via an intracellular pathway | |
US6740512B1 (en) | Neutral sphingomyelinase | |
EP0647275B2 (en) | Cloning and expression of gonadotropin-releasing hormone receptor | |
RU2003129500A (en) | METHODS FOR IDENTIFICATION OF COMPOUNDS FOR REGULATION OF MUSCLE WEIGHT OR FUNCTION USING RECEPTORS OF RELEASING FACTOR OF CORTICOTROPINE | |
CN1484650B (en) | Urocortin proteins and uses thereof | |
Richards et al. | Analysis of the promoter elements necessary for IL-4 and anti-CD40 antibody induction of murine Fc epsilon RII (CD23): comparison with the germline epsilon promoter. | |
Popova et al. | Chimeric G alpha s/G alpha i2 proteins define domains on G alpha s that interact with tubulin for beta-adrenergic activation of adenylyl cyclase. | |
WO1997033550A2 (en) | Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression | |
Johansson et al. | Tissue specific basal expression of soluble murine epoxide hydrolase and effects of clofibrate on the mRNA levels in extrahepatic tissues and liver | |
Jin et al. | Induction of anti-metallothionein antibody and mercury treatment decreases bone mineral density in mice | |
Adams et al. | Identification of a novel parathyroid hormone-responsive gene in human osteoblastic cells | |
EP0538395A4 (en) | Nucleic acid sequences encoding a human dopamine d 1? receptor | |
US5750366A (en) | Cloning and expression of gonadotropin-releasing hormone receptor | |
WO2003070916A3 (en) | Dna encoding snorf44 receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 507986 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2384358 Country of ref document: CA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 73207/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001952456 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2001952456 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001952456 Country of ref document: EP |